QuidelOrtho Corporation (QDEL)
QuidelOrtho Corporation operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $14.63, up 4.60% on the session, giving a market capitalisation of $997.9M. On trailing twelve-month figures it carries a trailing P/E of -0.95, a net margin of -39.2%. Its beta of 0.69 implies it has historically moved less than the broad market.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QuidelOrtho Corporation is most often compared with the following Healthcare names: